• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders.

作者信息

Fillmore Nathanael R, La Jennifer, Wu Julie Tsu-Yu, Corrigan June K, Branch-Elliman Westyn, Monach Paul, Brophy Mary T, Do Nhan V, Munshi Nikhil C

机构信息

VA Boston Healthcare System, Boston, MA.

Department of Medicine, Harvard Medical School, Boston, MA.

出版信息

Blood Adv. 2023 Nov 14;7(21):6767-6770. doi: 10.1182/bloodadvances.2023011063.

DOI:10.1182/bloodadvances.2023011063
PMID:37647600
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10659994/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0625/10659994/1b17cc0d834c/BLOODA_ADV-2023-011063-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0625/10659994/1b17cc0d834c/BLOODA_ADV-2023-011063-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0625/10659994/1b17cc0d834c/BLOODA_ADV-2023-011063-gr1.jpg

相似文献

1
Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders.即使在接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）加强针后，浆细胞疾病患者的新型冠状病毒肺炎（COVID-19）突破性感染仍有所增加。
Blood Adv. 2023 Nov 14;7(21):6767-6770. doi: 10.1182/bloodadvances.2023011063.
2
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.加强针接种后的抗体反应对晚期癌症患者 SARS-CoV-2 突破感染和疾病结局的影响：Vax-on-Third 研究的前瞻性分析。
Curr Oncol. 2023 May 17;30(5):5103-5115. doi: 10.3390/curroncol30050386.
3
Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.最后一剂 COVID-19 疫苗接种时间和完全（加强）接种疫苗的医护人员中的 SARS-CoV-2 突破感染。
J Hosp Infect. 2023 Feb;132:46-51. doi: 10.1016/j.jhin.2022.11.016. Epub 2022 Dec 5.
4
Limited enhancement of antibody and B-cell responses to prototype booster vaccination following SARS-CoV-2 Delta breakthrough infection.在SARS-CoV-2 Delta突破性感染后，对原型加强疫苗接种的抗体和B细胞反应增强有限。
J Med Virol. 2023 Feb;95(2):e28540. doi: 10.1002/jmv.28540.
5
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.在英国，加强针接种或突破性感染后对 SARS-CoV-2 奥密克戎 BA.4/5 变异株的保护作用。
Nat Commun. 2023 May 16;14(1):2799. doi: 10.1038/s41467-023-38275-1.
6
Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.奥密克戎 BA.1 突破性感染灭活 COVID-19 疫苗接种者诱导了针对不同奥密克戎亚谱系的抗体和 T 细胞反应的不同模式。
Emerg Microbes Infect. 2023 Dec;12(1):2202263. doi: 10.1080/22221751.2023.2202263.
7
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.接种疫苗一年后造血干细胞移植和细胞治疗受者的 SARS-CoV-2 反应性抗体衰减、加强效应和突破性 SARS-CoV-2 感染。
Bone Marrow Transplant. 2023 May;58(5):567-580. doi: 10.1038/s41409-023-01946-0. Epub 2023 Feb 28.
8
Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.同时接种抗 SARS-CoV-2 和流感疫苗的医护人员的安全性概况和 SARS-CoV-2 突破感染：一项意大利观察性研究。
Vaccine. 2023 Aug 31;41(38):5655-5661. doi: 10.1016/j.vaccine.2023.07.043. Epub 2023 Aug 4.
9
Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.COVID-19 患者在突破感染 SARS-CoV-2 变异株 Delta、Omicron-BA.1 和 Omicron-BA.5 期间的免疫反应。
Front Immunol. 2023 Jul 13;14:1150667. doi: 10.3389/fimmu.2023.1150667. eCollection 2023.
10
SARS-CoV-2 vaccine breakthrough infections in Virginia, January 17, 2021 - June 30, 2021.2021 年 1 月 17 日至 6 月 30 日弗吉尼亚州的 SARS-CoV-2 疫苗突破性感染。
Vaccine. 2023 Feb 10;41(7):1295-1298. doi: 10.1016/j.vaccine.2023.01.041. Epub 2023 Jan 20.

引用本文的文献

1
Pulmonary aspergillosis in US Veterans with COVID-19: a nationwide, retrospective cohort study.美国新冠肺炎退伍军人的肺曲霉病：一项全国性回顾性队列研究。
Antimicrob Steward Healthc Epidemiol. 2025 Jan 30;5(1):e28. doi: 10.1017/ash.2024.476. eCollection 2025.
2
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.用于因新冠肺炎住院的免疫功能低下患者的免疫调节剂：一项随机对照试验的荟萃分析。
EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar.

本文引用的文献

1
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).《后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件》。
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
2
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.超高风险多发性骨髓瘤患者经密集抗 CD38 抗体治疗后对 COVID-19 加强疫苗接种的免疫反应：来自英国骨髓瘤（MUK）九项 OPTIMUM 试验的结果。
Br J Haematol. 2023 Jun;201(5):845-850. doi: 10.1111/bjh.18714. Epub 2023 Mar 9.
3
Loss of anti-spike antibodies following mRNA vaccination for COVID-19 among patients with multiple myeloma.
mRNA 疫苗接种 COVID-19 后多发性骨髓瘤患者抗刺突抗体丢失。
Cancer Rep (Hoboken). 2023 May;6(5):e1803. doi: 10.1002/cnr2.1803. Epub 2023 Mar 9.
4
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).意义未明的单克隆丙种球蛋白病（MGUS）患者接种抗SARS-CoV-2疫苗“加强针”后的体液免疫反应
Mediterr J Hematol Infect Dis. 2023 Jan 1;15(1):e2023011. doi: 10.4084/MJHID.2023.011. eCollection 2023.
5
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.SARS-CoV-2 疫苗在单克隆丙种球蛋白病患者中的疗效：一项横断面研究。
Life Sci Alliance. 2022 Aug 12;5(12):e202201479. doi: 10.26508/lsa.202201479.
6
Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders.浆细胞疾病患者感染新型冠状病毒突破性感染的风险增加。
Blood. 2022 Aug 18;140(7):782-785. doi: 10.1182/blood.2022016317.
7
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.骨髓瘤患者接种 SARS-CoV-2 疫苗后中和抗体反应的决定因素。
J Clin Oncol. 2022 Sep 10;40(26):3057-3064. doi: 10.1200/JCO.21.02257. Epub 2022 Mar 8.
8
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma.抗CD38疗法会损害多发性骨髓瘤患者针对新冠病毒α和δ变体的疫苗反应。
Blood. 2022 Feb 10;139(6):942-946. doi: 10.1182/blood.2021013714.
9
Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study.COVID-19 疫苗接种与癌症患者 SARS-CoV-2 感染的关联：一项美国退伍军人事务部的全国性研究。
JAMA Oncol. 2022 Feb 1;8(2):281-286. doi: 10.1001/jamaoncol.2021.5771.
10
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network.COVID-19 疫苗接种在多发性骨髓瘤患者中的应用：欧洲骨髓瘤网络共识。
Lancet Haematol. 2021 Dec;8(12):e934-e946. doi: 10.1016/S2352-3026(21)00278-7. Epub 2021 Oct 28.